skin conductance (ESC) to measure sweat gland dysfunction, is valuable for detecting peripheral neuropathy. ESC was tested for association with DKD (estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 ) in 383 type 2 diabetes mellitus (T2D)-affected patients; diagnostic thresholds were determined in 540 patients. Methods: Relationships between ESC with eGFR and urine albumin:creatinine ratio (UACR) were assessed in 202 European Americans and 181 African Americans with T2D. Results: In 92 European American DKD cases and 110 T2D non-nephropathy controls, respectively, mean (SD) ages were 69 (9.7) and 61 (10.8) years, hemoglobin A1c (HbA1c) 7.4 (1.2) and 7.4 (1.3)%, eGFR 29.6 (12.2) and 87.8 (14.2) ml/min/1.73 m 2 , and UACR 1,214 (1,705) and 7.5 (5.8) mg/g. In 57 African American cases and 124 controls, respectively, mean (SD) ages were 64.0 (11.9) and 59.5 (9.7) years, HbA1c 7.4 (1.3) and 7.5 (1.7)%, eGFR 29.6 (13.3) and 90.2 (16.2) ml/min/1.73 m 2 , and UACR 1,172 (1,564) and 7.8 (7.1) mg/g. Mean (SD) ESC (μS) was lower in cases wide and approximately 20-40% of patients with longstanding T2D develop DKD, noninvasive highly accurate screening tests to detect which patients with T2D are at high risk for DKD would be useful. Earlier detection of nephropathy will increase the likelihood that treatments such as improving glycemic and hypertension control and use of renin-angiotensin-aldosterone-system blocking agents can delay nephropathy progression and reduce associated cardiovascular complications [5, 6] . Many patients with DKD do not have albuminuria [7] . Therefore, it is critical that screening tests be able to detect reduced estimated glomerular filtration rate (eGFR).
Electrochemical skin conductance (ESC) to measure sweat gland dysfunction has proven useful for detecting and monitoring peripheral and autonomic neuropathic complications in patients with T2D [8, 9] . In addition to diabetic neuropathy, 2 reports measuring ESC with the Sudoscan ® device showed association with DKD [10, 11] .
As such, there may be benefit to measuring ESC in patients with T2D to noninvasively identify those likeliest to have DKD. Urine testing for albuminuria, measurement of serum creatinine concentration, and eGFR can then be performed in individuals with reduced ESC, decreasing the need for conducting these more expensive tests in the broader population. Because ESC can be noninvasively measured at low cost, large numbers of T2D-affected patients can be rapidly screened and the highrisk subset referred for further renal (and neurologic) evaluation. Strategies such as this may improve early detection and monitoring of DKD, with the potential to reduce progression to end-stage kidney disease, requiring renal replacement therapy and decrease associated cardiovascular complications. The present analyses measured ESC in African Americans and European Americans with T2D to detect associations with DKD and develop threshold values useful in the clinic.
Methods

Study Populations
The study population comprised self-described African Americans and European Americans with T2D recruited from the Diabetes Heart Study, the African-American Diabetes Heart Study, internal medicine, and nephrology clinics at Wake Forest School of Medicine (WFSM) [12, 13] . Inclusion criteria were diabetes mellitus diagnosed after the age of 25 years and active hyperglycemic treatment with oral agents and/or insulin in the absence of diabetic ketoacidosis. CKD was attributed to diabetes after medical record review by a single investigator (B.I.F.), based on nephropathy first detected after ≥ 5 years diabetes duration in the absence of other known causes of kidney disease. In the primary analyses, the presence of nephropathy was based on a Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation eGFR <60 ml/min/1.73 m 2 (irrespective of the level of proteinuria) in newly recruited DKD cases [14] . Secondary analyses were then performed, including all DKD cases from the primary analyses, as well as previously recruited DKD cases based on the definition of a urine albumin:creatinine ratio (UACR) >30 mg/g and/or CKD-EPI eGFR <60 ml/min/1.73 m 2 [11] . T2D non-nephropathy controls in the primary and secondary analyses were the same subjects, all with eGFR >60 ml/min/1.73 m 2 and UACR <30 mg/g. Exclusion criteria included amputations (precluding accurate ESC testing), the presence of cardiac pacemakers and/or implanted defibrillators, malignancy (except non-melanoma skin cancer) within the prior year, receipt of chemotherapy within the prior year, prior dialysis treatments, or kidney transplantation. All participants provided written informed consent and the study was approved by the Institutional Review Board at WFSM.
Laboratory Testing
Laboratory testing included assessment of glycemic control based on the hemoglobin A1c (HbA1c) and measurement of serum creatinine concentration using a kinetic modification of the Jaffe procedure (Beckman Coulter, Fullerton, Calif., USA) at Wake Forest Baptist Medical Center. Spot urine albumin and creatinine concentrations were measured at LabCorp, Inc. (Burlington, N.C., USA) for computation of the UACR.
ESC
As previously reported, ESC was measured using the Sudoscan ® device (Impeto Medical; Paris, France) during routine clinic visits to assess sweat gland dysfunction [11, 15] . ESC was measured through the extraction of chloride ions from sweat glands on the palms and soles (reverse iontophoresis) and chronoamperometry. Both palms and soles were cleansed with a moist towel and placed on two large stainless steel electrodes that had been disinfected with Surfa'Safe ® (Laboratoires Anios; LilleHemmes, France). Participants were asked not to move during the approximate 2-minute test. Electrodes were connected to a computer that recorded time/ampere curves as gentle stimulation was applied in a graded fashion via low voltage direct current (<4 V) on the anode. This generated a voltage through reverse iontophoresis on the cathode that is proportional to the flow of sweat gland chloride ions. The ratio between the generated current and the constant voltage applied, also known as the ESC, was measured in μS (microsiemens) between the anode and the cathode. Values were computed for skin conductance in each palm and each sole, and as a measure of asymmetry between the 2 hands and the 2 feet. Mean ESC in the hands, mean ESC in the feet, and mean global skin conductance computed as 0.5 * (reflecting (right + left hand)/ 2 + (right and left foot)/2) in each participant were evaluated for association with eGFR and UACR.
Statistical Analyses
Descriptive summary statistics were computed separately based on the presence of kidney disease and race/ethnicity. Unadjusted comparisons of the distribution of observed conductance and other demographics variables were performed between race/ ethnicity by kidney disease status. For continuous outcomes, these comparisons were dependent upon the Wilcoxon 2-sample test, a non-parametric test known to be robust to deviations from the normality assumption. Chi-square tests were used for comparing categorical outcomes by kidney disease status.
Generalized linear models were fitted to test for associations between mean skin conductance and kidney function measures. CKD-EPI eGFR values above 120 ml/min/1.73 m 2 were winsorized at 120. The Box-Cox method was applied to identify the appropriate transformation best approximating the distributional assumptions of conditional normality and homogeneity of variance of the residuals [16] . These methods suggested taking the logarithm of UACR. There was no need to transform the CKD-EPI eGFR. We ran an unadjusted model to test for association between UACR and CKD-EPI GFR followed by adjusted models that successively included age, gender, HbA1c and body mass index (BMI) as covariates. Analyses were run stratified by race/ethnicity to protect against the potential confounding effect of race/ethnicity.
Receiver operating characteristic (ROC) curves were generated using the predicted probabilities generated from a logistic regression model with the log-odds of eGFR <60 ml/min/1.73 m 2 as the outcome and participant age and mean ESC in feet as predictors. This model was developed and analyzed because it yielded predicted probabilities that were strongly correlated with a proprietary DKD measure that is provided by the Sudoscan ® device (absolute value of the Spearman rank correlation 0.96). The (0, 1) point on the ROC curve corresponds to the 1-sensitivity and specificity of the ideal diagnostic test that correctly classifies all diseased and all disease-free individuals [17, 18] . The point closest to (0, 1) has recently been shown to outperform other competing approaches, especially when the distribution of the biomarker is skewed [19] . The estimated cut-point, specificity, sensitivity, negative predicted probability (NPV), and positive predicted probability (PPV) were computed.
Results
The primary analyses contrasted ESC in 149 newly recruited DKD cases with an eGFR <60 ml/min/1.73 m 2 (57 African American; 92 European American) with those in 234 T2D non-nephropathy controls with eGFR >60 ml/ min/1.73 m 2 Table 2 displays the results of continuous relationships between eGFR and log UACR with measures of ESC; the initial model was unadjusted, followed sequentially by models adjusting for age and gender; age, gender, and BMI; and a full-model including age, gender, BMI, and HbA1c. Significant relationships between hands ESC, feet ESC, and global ESC with eGFR were seen in all models including the fully adjusted model in African Americans and European Americans. In contrast, log UACR was associated only with ESC in European Americans. A metaanalysis was performed across race-groups and revealed highly significant results for ESC association with eGFR and UACR (table 2) . Association results were always in the same direction in both race/ethnic groups.
Results of the logistic regression analyses assessing relationships between ESC and UACR >30 mg/g, UACR >300 mg/g, eGFR <60 ml/min/1.73 m 2 , and the presence of DKD defined as an eGFR <60 ml/min/1.73 m 2 and/or UACR >30 mg/g are presented in table 3. The same adjustments were applied as in the analysis of continuous outcomes. Hands ESC, feet ESC, and global ESC were significantly associated with UACR >30 mg/g, UACR >300 mg/g, eGFR <60 ml/min/1.73 m 2 , and with DKD in both race-groups. , respectively; and median UACR was 103 mg/g in African American cases and 99 mg/g in European American cases. UACR values >30 and >300 mg/g, respectively, were recorded in 83.3 and 53.3% of European American cases and 89.8 and 38.0% of African American cases. Although the additional cases included in the secondary analyses had less severe nephropathy than those in the primary analyses, statistically significant associations were detected between feet ESC, hands ESC, and global ESC in both race-groups with eGFR in continuous analyses, and between log UACR in European Americans (online suppl. table 2). Logistic regression analyses in the full sample revealed significant associations between feet ESC, hands ESC, and global ESC with eGFR <60 ml/min/1.73 m 2 and UACR >300 mg/g in both race-groups (online suppl. table 3). Table 4 displays the predicted probability cut-off values for detection of eGFR <60 ml/min/1.73 m 2 in the full sample of 540 patients with T2D; area under the curve (AUC), sensitivity, specificity, NPV, and PPV are reported by race. Thresholds were developed for this screening test to detect diabetic individuals at high risk for DKD who might benefit from additional lab testing. Figure 1 displays ROC curves and diagnostic performance of the predicted probability of the logistic model that includes age and mean ESC in feet as covariates and eGFR <60 ml/min/1.73 m 2 as the outcome in African Americans and European Americans with T2D. In African Americans with T2D, the optimal cut-point for predicted probability of detecting an eGFR <60 ml/ min/1.73 m 2 was 37.6% with an AUC of 0.74; this threshold had sensitivity of 0.69, specificity of 0.70, and a NPV 0.87. In European Americans with T2D, the optimal cutpoint for predicted probability of detecting eGFR <60 ml/ min/1.73 m 2 was 44.4% with an AUC of 0.74; this threshold had a sensitivity of 0.69, a specificity of 0.73, and a NPV 0.87.
Discussion
Given the worldwide epidemic of T2D and associated DKD, validating noninvasive methods for detecting and potentially monitoring diabetic microvascular complications is important. Measures of ESC were associated with DKD in Hong Kong Chinese, with replication in African Americans having milder nephropathy [10, 11] . However, the assessment of ESC associations with more advanced DKD was not possible in the initial US study. Here, a larger number of African Americans and European Americans with T2D and eGFR <60 ml/min/1.73 m 2 were recruited and tested. Significant evidence of association was confirmed between both eGFR and albuminuria with ESC measured with the Sudoscan ® device in this population having Stages 3 to 5 CKD related to T2D. In addition, all 540 Wake Forest study participants with T2D tested with the Sudoscan ® device were included in a secondary analysis capturing a broader range of kidney function and albuminuria. In African Americans and European Americans, this analysis revealed predict- In addition to the utility of ESC for diagnosing and monitoring diabetic peripheral neuropathy and autonomic neuropathy, the results in this report support the potential use of ESC for identifying individuals with higher likelihood of DKD in populations with T2D. In contrast, mean HbA1c values between groups did not differ significantly and would not be useful in risk stratification for DKD. Additional studies are warranted to determine whether the rate of decline in eGFR and changes in albuminuria are detectable with the Sudoscan ® device for monitoring disease remission or progression with therapy. ESC measurements appear to be useful for screening populations with T2D to rapidly detect those likely to have DKD, and would be applicable in underdeveloped areas without ready access to blood and urine testing for nephropathy. Although urine dipsticks can detect albuminuria, many diabetic patients will develop DKD in the absence of albuminuria and those with low-level proteinuria may not lose kidney function. The high reproducibility of ESC testing for detection of reductions in eGFR makes it particularly attractive, compared to more variable measures such as proteinuria [8, 20, 21] . We chose to focus association results on the mean ESC in feet and participant age, because of their stronger association with eGFR compared to when association results were focused on mean ESC in hands or global ESC. The present analyses included 540 individuals with T2D and simultaneous measures of ESC, kidney function, and albuminuria. A potential limitation was that albuminuria results were based on a single reading and albuminuria can vary over time. This limitation is present in many reports and is expected to have the greatest impact in those with low-level albuminuria, where fluctuations can reclassify patients between having microalbuminuria and normoalbuminuria. Therefore, the main analyses focused on the end-point of reduced eGFR and UACR >300 mg/g, because higher UACR values reflect overt proteinuria. The present results were cross-sectional; as such, longitudinal follow-up assessing changes in ESC with progression and/or regression of nephropathy remain necessary. In addition, diagnostic performance may be overly optimistic, because the cut-offs were identified with the same dataset that was used to estimate the predicted probabilities. However, these diagnostic performances were similar to those obtained with the Sudoscan ® -DKD measure; this is a proprietary measure that was developed using an independent data set that was not from the WFSM. ESC has been extensively assessed in patients with type 1 diabetes for peripheral and autonomic neuropathy; however, studies on nephropathy phenotypes are yet to be performed in type 1 diabetes.
In conclusion, noninvasively measured ESC strongly associated with parameters of kidney disease in African Americans and European Americans with T2D. Race-specific ESC thresholds suggesting reduced kidney function (eGFR <60 ml/min/1.73 m 2 ) and macroalbuminuria (UACR >300 mg/g) are reported with relatively high sensitivity and excellent negative predictive values in individuals with T2D. ESC is likely to be useful for noninvasive screening in populations with diabetes to determine which individuals are likeliest to have nephropathy and would benefit from further laboratory testing and referral. ESC testing will be especially useful in settings where there is limited access to healthcare. Future studies should assess whether changes in ESC are associated with longitudinal change in eGFR and UACR in patients with DKD. This will determine whether a role exists for ESC to monitor progression of DKD, as in neuropathy. This would be valuable in patients who undergo intensification of glycemic and hypertension treatment and institution of renin-angiotensin-aldosterone-system blockade. Reduced ESC is strongly associated with albuminuria and reduced kidney function in African Americans and European Americans with T2D.
